Runcaciguat

Overview

Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF).

Application

Products | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Hypertension | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Guanylate Cyclase

Product Information

• Catalog No.: HY-109136
• CAS No.: 1402936-61-1
• Molecular Formula: C23H22Cl2F3NO3
• Molecular Weight: 488.33
• Purity: 99.31%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source